A detailed history of Shelton Capital Management transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Shelton Capital Management holds 53,984 shares of VRTX stock, worth $22 Million. This represents 0.65% of its overall portfolio holdings.

Number of Shares
53,984
Previous 47,708 13.16%
Holding current value
$22 Million
Previous $22.4 Million 12.28%
% of portfolio
0.65%
Previous 0.62%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$460.0 - $505.78 $2.89 Million - $3.17 Million
6,276 Added 13.16%
53,984 $25.1 Million
Q2 2024

Aug 13, 2024

BUY
$392.81 - $485.53 $90,346 - $111,671
230 Added 0.48%
47,708 $22.4 Million
Q1 2024

May 15, 2024

BUY
$407.69 - $446.08 $19.4 Million - $21.2 Million
47,478 New
47,478 $19.8 Million
Q4 2023

Feb 14, 2024

BUY
$343.0 - $410.68 $4.4 Million - $5.27 Million
12,821 Added 42.31%
43,124 $17.5 Million
Q3 2023

Nov 14, 2023

BUY
$338.18 - $362.46 $10.2 Million - $11 Million
30,303 New
30,303 $10.5 Million
Q2 2023

Aug 10, 2023

BUY
$314.42 - $351.91 $285,178 - $319,182
907 Added 3.97%
23,769 $8.36 Million
Q1 2023

May 11, 2023

BUY
$283.23 - $323.1 $740,363 - $844,583
2,614 Added 12.91%
22,862 $7.2 Million
Q4 2022

Feb 13, 2023

SELL
$285.76 - $321.48 $1.39 Million - $1.56 Million
-4,854 Reduced 19.34%
20,248 $5.85 Million
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $94,197 - $105,102
344 Added 1.39%
25,102 $7.27 Million
Q1 2022

May 12, 2022

BUY
$221.42 - $260.97 $106,503 - $125,526
481 Added 1.98%
24,758 $6.46 Million
Q4 2021

Feb 11, 2022

BUY
$177.01 - $223.45 $84,433 - $106,585
477 Added 2.0%
24,277 $5.33 Million
Q3 2021

Nov 15, 2021

SELL
$181.39 - $202.99 $1.52 Million - $1.71 Million
-8,400 Reduced 26.09%
23,800 $4.32 Million
Q2 2021

Aug 12, 2021

BUY
$187.49 - $221.1 $6.04 Million - $7.12 Million
32,200 New
32,200 $6.49 Million
Q1 2021

May 14, 2021

SELL
$207.02 - $241.31 $4.52 Million - $5.26 Million
-21,812 Closed
0 $0
Q2 2020

Aug 12, 2020

BUY
$225.48 - $295.8 $52,762 - $69,217
234 Added 1.08%
21,812 $6.33 Million
Q1 2020

May 13, 2020

BUY
$199.77 - $247.81 $4.31 Million - $5.35 Million
21,578 New
21,578 $5.13 Million
Q4 2019

Feb 11, 2020

SELL
$166.71 - $223.91 $121,865 - $163,678
-731 Reduced 3.22%
21,955 $4.81 Million
Q3 2019

Nov 13, 2019

SELL
$166.23 - $187.09 $4.33 Million - $4.87 Million
-26,052 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$164.61 - $190.37 $3.56 Million - $4.11 Million
21,601 Added 485.31%
26,052 $4.78 Million
Q1 2019

May 10, 2019

SELL
$163.73 - $194.7 $3.23 Million - $3.84 Million
-19,744 Reduced 81.6%
4,451 $24.2 Million
Q4 2018

Jan 31, 2019

BUY
$151.91 - $192.21 $3.68 Million - $4.65 Million
24,195 New
24,195 $4.01 Million
Q2 2018

Aug 10, 2018

SELL
$145.72 - $169.96 $3.67 Million - $4.28 Million
-25,195 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$151.6 - $177.13 $321,695 - $375,869
2,122 Added 9.2%
25,195 $4.11 Million
Q4 2017

Feb 06, 2018

BUY
$137.28 - $155.55 $838,918 - $950,566
6,111 Added 36.03%
23,073 $3.46 Million
Q2 2017

Aug 14, 2017

BUY
N/A
5,111 Added 28.45%
23,073 $2.97 Million
Q1 2017

Nov 28, 2017

BUY
N/A
17,962 New
17,962 $1.96 Million
Q3 2016

Dec 04, 2017

BUY
N/A
16,962
16,962 $1.25 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Shelton Capital Management Portfolio

Follow Shelton Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shelton Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Shelton Capital Management with notifications on news.